Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors (Q39009781)

8 September 2017

1 reference

title

Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors (English)

1 reference

8 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Daphne Day

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

15 November 2016

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

571-584

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40259-016-0204-3

5 June 2020

exact match

0 references

cites work

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

The PD-1 pathway in tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Ipilimumab in patients with melanoma and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0204-3

10.1007/S40259-016-0204-3

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27848165%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference